Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention

Recruiting

• Conditions: Acute Myocardial Infarction

• Registration Number: NCT06669520
• Lead Sponsor: The Third Xiangya Hospital of Central South University

Brief Summary

This research will explore the association between blood serum renalase and microcirculation obstruction in patients with acute myocardial infarction (AMI) after primary percutaneous coronary intervention (PCI). The investigators aim to identify potential risk factors for microcirculation obstruction in AMI patients after PPCI.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-08-01
• Status Verified: 2024-10
• Study First Submitted: 2024-10-29
• Study First Submitted QC: 2024-10-30
• Last Update Submitted: 2024-10-30
• Study First Posted: 2024-11-01
• Last Update Posted: 2024-11-01
• Primary Completion: 2025-10-01
• Study Completion: 2025-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Age ≥ 18 years;
2. STEMI symptom onset time < 12 hours;
3. STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias;
4. High-risk NSTEMI;
5. Emergency PCI;
6. Voluntary informed consent.

Exclusion Criteria

1. Non-obstructive acute myocardial infarction;
2. Severe chronic kidney disease (defined as estimated glomerular filtration rate < 20 mL/min per 1.73 m²);
3. Life expectancy < 1 year;
4. Pregnant or planning to become pregnant;
5. Emergency PCI failure.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Participants with Microvascular Obstruction Assessed by Contrast-Enhanced Magnetic Resonance Imaging 3-7 Days After Percutaneous Coronary Intervention.	3-7 days after PPCI	Microvascular obstruction (MVO) was qualitatively recognized as a subendocardial lack of enhancement at first-pass perfusion (FPP) sequences and as a hypointense region within the hyperintense infarcted area at early gadolinium enhancement (EGE) and late gadolinium enhancement (LGE) sequences.

Trial Locations

Locations (1)

The Third Xiangya Hospital of Central South University; 🇨🇳 Changsha, Hunan, China